Clearmetrx

Industry overview:

According to Berkley Research Group, 340B gross sales across the 340B program are expected to grow from $142B in 2022 to $280B in 2026.

The program is a government-run program that helps provide discounted prescription drugs to low-income and uninsured Americans. 340B participants include hospitals, clinics, and other healthcare providers.

It is likely that the 340B program will continue to grow and be highly relevant in the healthcare industry. The program is benefiting from increased attention from policymakers and the healthcare industry. Additionally, the 340B program is expected to continue growing in popularity and gross sales. This growth is due in part to the increasing number of low-income and uninsured Americans, as well as the increasing cost of prescription drugs.

Quick overview of the program:

- 340B gross sales across the program are expected to grow from $116B in 2021 to $280B in 2026
- The 340B program is a government-run healthcare program that helps provide discounted prescription drugs to low-income and uninsured Americans
- 340B participants include hospitals, clinics, and other healthcare providers
- The 340B program is administered by the Centers for Medicare & Medicaid Services (CMS)

Tailored to fit the exact needs of healthcare professionals, we offer a comprehensive array of reports to ensure the value we provide is always beyond expectations.

We simplify your data process so you can focus on providing care!

https://hipaasecure.formstack.com/forms/340metrx

Myths and facts about

Click on our website to learn more about CM

Data is a very Effective Tool To Improve Medication Adherence! Click on our website to read more about ClearMetrx

"Compliance is a passive behavior in which a patient is following a list of instructions from the doctor." "Adherence is a more positive, proactive behavior, which results in a lifestyle change by the patient, who must follow a daily regimen, such as wearing a prescribed brace"